Skip to main content

Day: April 28, 2021

Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14

Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Global Small Cap Conference being held May 13-14, 2021. Lixte will be presenting on Thursday, May 13, 1:00-1:20 pm Eastern Time. Investors may register and consult the conference agenda by visiting the event website. John S. Kovach, M.D., Lixte founder and chief executive officer, commented, “Our lead drug candidate, LB-100, is currently being studied in clinical investigations targeting some of the most aggressive cancers. If the improvement of standard treatments for diverse...

Continue reading

TAAT™ Lifestyle & Wellness Ltd. Name Change to TAAT™ Global Alternatives Inc. Has Taken Effect as of 9:30 am EDT on Wednesday, April 28, 2021

LAS VEGAS and VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — TAAT™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT™”) announces that as of 9:30 am EDT today (Wednesday, April 28, 2021), the Company’s name has officially changed from TAAT™ Lifestyle & Wellness Ltd. (the “Former Name”) to TAAT™ Global Alternatives Inc. (the “Updated Name”), as announced in a press release dated Monday, April 26, 2021. No change has been made to the Company’s ticker symbol as a result of this name change, and the Company’s common shares will continue to trade under the ticker “TAAT” on the Canadian Securities Exchange. The CUSIP number assigned to the Company’s shares following the name change to the Updated Name is 87320M101 (ISIN: CA87320M1014). No action is required to be taken...

Continue reading

Manny Pacquiao & The Manny Pacquiao Foundation Sign Endorsement Deal with LTNC Takeover Industries

ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) — Labor SMART, Inc. (LTNC) (the “Company”), announced that its recently acquired subsidiary, Takeover Industries Inc., has officially signed an endorsement deal with Manny Pacquiao and The Manny Pacquiao Foundation. Boxing champion Manny Pacquiao, is regarded as one of the greatest professional boxers of all-time and is the only boxer in history to win titles in eight different weight classes. In addition to serving as a Senator of the Philippines, Pacquiao is also the founder of The Manny Pacquiao Foundation (MPF), a California based non-profit, fighting for those less fortunate and spreading hope around the world. Manny Pacquiao said, “To create a partnership with an innovative company like Takeover Industries that is focused on health and athletic performance with NXT LVL Hydrogen Water...

Continue reading

Altair International Corp. Provides Corporate Update

PITTSBURGH, April 28, 2021 (GLOBE NEWSWIRE) — Altair International Corp. (“Altair” or the “Company”) (OTC: ATAO) is pleased to provide the following updates on various events and initiatives. Tier Change After a lengthy review process, which began shortly before the New Year, Altair has been ‘upgraded’ to the OTCQB tier on OTCMarkets.com. We believe that this tier change will bring increased visibility to the company, in addition to potentially opening new doors to outside investment. Interested parties are encouraged to view the Company’s corporate profile at https://www.otcmarkets.com/stock/ATAO/profile. EV Lithium Solutions, Inc. (“EVLS”) Development and testing continue on our recently acquired battery technology, and said development has made significant advances in the past month. Our current focus has been on perfecting...

Continue reading

Affinor Growers to Use TESLA as Alternative Energy Provider

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — Affinor Growers Inc. (“Affinor” or the “Company”) (CSE: AFI; OTCQB: RSSFF) is pleased to announce it has chosen TESLA as the alternative energy provider for the company’s Abbotsford BC vertical growing operation. The solar PV system will offset electrical consumption, lowering operations costs throughout the year. Outfitted with Affinor’s patented vertical farming technology, the company’s 15,000 sq ft greenhouse is scheduled for lettuce and strawberry production this summer. A license application to Health Canada for a cannabis micro cultivation operation within a walled off section of the greenhouse is also expected this summer. In addition to lower energy costs, TESLA Power Walls will completely support the water irrigation system and ensure continuous power during...

Continue reading

Savosolar wins tender in China to deliver solar heating system to Guangzhou Power Supply Bureau, Guangdong Power Grid Co., Ltd.

Savosolar Plc Company Announcement, Insider information                    28 April 2021 at 3.15 p.m. (CEST) Savosolar wins tender in China to deliver solar heating system to Guangzhou Power Supply Bureau, Guangdong Power Grid Co., Ltd. Savosolar Plc is selected as the winning bidder to deliver a solar heating system to Guangzhou Power Supply Bureau, Guangdong Power Grid Co., Ltd. (later Guangzhou Power Supply) in China. The value of the system is approximately EUR 500 thousand. Both parties are aiming to finalize the contract within four weeks’ time. Once the contract is signed, the delivery of the system is expected in the autumn 2021 and to be operational by the end of this year. Savosolar large collectors will be installed on a tracker following the sun and maximizing the clean energy output from limited installation space. Project...

Continue reading

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ETSOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent...

Continue reading

Company announcement no 8/2021 – Prospectus and Public listing of Bond, Idavang A/S

Idavang is pleased to announce its prospectus on the listing on Nasdaq Copenhagen A/S of its 75.000.000 EUR bond issued in November 2020 (due 2025) with ISIN DK0030472618, with the 29th April 2021 as first trading day. A copy of the listing prospectus is available for download on its website (https://www.idavang.com/#investors) by eligible investors. No offering of Bonds takes place by Idavang A/S in connection with the publication of the Prospectus DisclaimerThe distribution of the Idavang Prospectus and the offering or sale of the Bonds in certain jurisdictions may be restricted by law. Persons into whose possession the Idavang Prospectus comes are required by Idavang to inform themselves about and to observe any such restriction. The Manager has not authorized the whole or any part of the Idavang Prospectus and makes no representation...

Continue reading

illimity Presents First Voluntary Non-Financial Statement and Announces it Achieved Carbon Neutrality in 2020

The materiality analysis involved over 740 stakeholders, a group comprised of those inside and outside the bank, in determining the topics that are material for illimity. Five pillars in line with international trends were identified, ranging from the G20’s priorities to the new Stakeholder Capitalism Metrics:Principles of Governance: illimity’s Corporate Governance sees a Board of Directors, led by the Chairperson Rosalba Casiraghi, that is well-balanced in terms of gender. People: illimity was recognised as a Great Place to Work for the second consecutive year, with 85% of employees noting overall satisfaction and the gender pay-gap effectively closed. Prosperity: the Bank has introduced an ESG rating into its credit assessment and in 2020 has allocated financing of EUR 247 million to the relaunching of SMEs in difficulty. Planet and...

Continue reading

First Horizon Announces Public Offering of Depositary Shares Representing Series F Preferred Stock and Expected Redemption of Series A Preferred Stock

MEMPHIS, Tenn., April 28, 2021 (GLOBE NEWSWIRE) — First Horizon Corporation (NYSE: FHN) (“First Horizon”) announced today a public offering of depositary shares, each representing 1/4,000th interest in a share of its Non-Cumulative Perpetual Preferred Stock, Series F, $100,000 liquidation preference per share (equivalent to $25 per depositary share). First Horizon may grant the underwriters a 30-day option to purchase additional depositary shares solely to cover over-allotments, if any. First Horizon intends to use the net proceeds of this offering to redeem in full the outstanding shares of its Non-Cumulative Perpetual Preferred Stock, Series A, and related depositary shares (NYSE: FHN PRA); any remainder will be used for general corporate purposes. Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.